Developer of a cloud-based analytics platform designed to assist people and businesses in decision-making. The company's platform focuses on people analytics and workforce planning, allowing access to meaningful answers for business questions in real-time, from the cloud, with no dependency on technical resources, enabling businesses to shape business strategy and take action.
Provider of intelligence-driven marketing and sales automation services intended to help growing businesses make meaningful connections with their customers. The company's customer experience automation platform (CXA) offers marketing automation, email marketing, transactional email, sales automation, and customer relationship management (CRM), providing clients with a personalized, automation-first approach that allows teams to save time and effectively connect with customers.
Developer of reviews collection and management solutions designed to collect genuine texts and video reviews from happy customers. The company's platform helps increase advertisement click-through rate, lowers its cost-per-click, provides past customer reviews to build trust in the company, displays product review solutions for growing brands, manages online reputation across third-party platforms, and more, thereby helping brands build trust through review collection.
SparkLayer is the powerful platform that transforms your existing website into a fully featured B2B solution. Rapid to setup, simple to use, and integrates beautifully with your existing systems.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, includingmore